0 → 1.5M organic sessions / mo.
14,000 peer-reviewed articles over 11 years. The site that became the playbook for Experts Ink.
- Client
- USARx.com
- Market
- US · Nationwide
- Window
- 2012 → 2023 · 11 years
- Organic sessions / mo
- 1.5M (2023 peak)
- Articles published (peer-reviewed)
- 14,000+
- Ranked keywords (top-10)
- 48,000+
- Google core-update survival (tenure)
- 7 / 7
USARx.com is where the playbook was born. Chris ran SEO and editorial there for 11 years.
Chris Riley ran SEO and editorial at USARx.com from 2012 through 2023. Across 11 years his team shipped 14,000 peer-reviewed articles, drug monographs, and condition pages, growing the property from zero to a 1.5M organic sessions / mo peak in 2023. USARx is where Chris became a medical writer himself, where he first worked with Alex (then doing content at GoodRx), and where the in-the-trenches version of the Experts Ink playbook was built. Chris departed USARx in 2023 and stood up Experts Ink around everything the 11-year run had proven.
The build started with the editorial bar, not the keyword list. Every page was written or reviewed by a named, credentialed clinician, used primary sources, and shipped with a disclosure the reader could actually click. Volume followed. It always does. The moat was the editorial paper trail Google (and every reader) could verify.
- 01
Clinical editorial bar
Wrote the editorial bar with a specialty lead before a single keyword was mapped. No shortcuts on what counts as a credible claim.
- 02
Topical authority map
Built a pillar / cluster topical model around the commercial search intents that actually drive pipeline for this vertical.
- 03
Named reviewer program
Specialty-matched reviewers on every clinical page. Linked-out professional profiles. Every sign-off archived for audit.
Rankings are the first receipt.
Trust is the asset.
Peer-reviewed medical content does two jobs. It ranks. Then, quietly, it does the harder one: it tells every reader, buyer, regulator, partner, and supplier that the brand is run by people who take healthcare seriously. Eyeballs are incidental. Credibility is the compounding asset.
- 01
Editorial cited by
Axios, STAT News, KHN, NBC News syndication, and pharma payer teams covering drug-pricing. The brand stopped being a coupon site; it became the source journalists quoted.
- 02
Clinician pipeline
Pharmacists and MDs pitched USARx to write for, not the other way around. Byline inventory outran publishing velocity for the last four years of Chris's tenure.
- 03
Partnership inbound
Telehealth brands, employer benefits platforms, and hospital systems cited USARx's editorial authority in partnership memos. Deals closed because of the paper trail, not the traffic.
- 04
Acquirer diligence
Medical-editorial quality was named a transaction-value driver in Chris's 2023 exit process, separate from the organic-traffic asset.
“USARx is where I learned what healthcare content actually is. Eleven years, 14,000 articles, one standard of evidence: real clinicians, named, on every piece. That's the playbook I took into Experts Ink.”
Give us a brief.
We'll send back a plan.
Tell us the brand, the reader, and the goal. Within three business days a credentialed clinician on our desk will hand-write a free editorial teardown and a 90-day roadmap. Yours to keep, even if you never hire us.
- · Written by a real MD / PharmD / RD, not a sales rep
- · 3 business days
- · No meeting required